Evaluating the Safety and Effectiveness of the Tixel Fractional System in the Treatment of Photodamage at Low Settings

Exclusion Criteria

• •1. Past treatment with Tixel device.
• •2. The subject may not undergo treatment by the Tixel device according to the device's contra-indications for use, as defined in the User Manual and in the Instructions for Use and by any other labeling of the device.
• •3. Subjects who, in the investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability.
• •4. Female subjects who are pregnant or planning to become pregnant.
• •5. Subjects with significant exposure to critical amounts of ultraviolet light (Suntan).
• •6. Subjects who have had the following treatments:
• •1. a cosmetic procedure to improve rhytides (i.e. Carbon Dioxide/Erbium/similar laser/fractional resurfacing, radiofrequency treatment) within 3 months
• •2. prior facial treatments with laser, surgical, chemical or light-based facial treatments within the previous 3 months, including botulinum toxin injections or microdermabrasion.
• •3. Injectable filler in cheeks (mid face) temples and in the upper face area to be treated within 3 months of investigation.
• •7. Any subject who has visible scars or other visible changes over the treated areas that may affect evaluation of response and/or quality of photography.
• •8. Subjects with any type of active cut, wound, inflammation, premalignant or malignant lesion or active bacterial, viral, fungal, or herpetic infection on the skin on the designated treatment sites or in close proximity to it.
• •9. Existing or history of the following (when discussing skin conditions, refers only to the face):
• •1. skin malignancy, or any diagnosis of suspected malignancy
• •2. Collagen vascular or bleeding disorder
• •3. Immunosuppression or autoimmune disease
• •4. Active acne vulgaris, herpes simplex virus or any existing skin condition/disease that in the investigator's opinion would interfere with the evaluation of the safety of the study treatment and evaluation.
• •5. Any skin pathology which can induce bullous lesions, urticaria, or demonstrate a Koebner phenomenon (psoriasis, lichen planus, etc.).
• •6. Any disease that inhibits pain sensation
• •7. History of keloid formation, or hypertrophic scarring
• •8. Conditions affecting healing rate (diabetes mellitus I or II)
• •9. neuromuscular disorders
• •10. Subjects who have used, within 30 days, any medication that can cause dermal hypersensitivity or affect skin characteristics over the treated area (i.e. topically applied retinoids, hydroquinone, chemical peel of any strength: glycolic acid, lactic acid, salicylic acid)
• •11. Subjects who have used, systemic treatment which may induce dyspigmentation, such as amiodarone, clofazimine, or chloroquine.
• •12. Subjects currently taking or have taken an oral retinoid in the past six months; Subjects currently taking long-term oral corticosteroid treatment.
• •13. Concurrent therapy that, in the principal investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study treatment.
• •14. Subjects who anticipate the need for major surgery or overnight hospitalization during the study that can affect the study schedule or treatment evaluation.
• •15. Enrollment in any active study involving the use of investigational devices or drugs.
• •16. Any other cause per the principal investigator's discretion.